UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 222

Sortiert nach

Slow-Dissociation and Slow-Recombination Assumptions in Nonequilibrium Capillary Electrophoresis of Equilibrium Mixtures

Analytical chemistry (Washington), 2011-10, Vol.83 (19), p.7582-7585

2011

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and Protection of Aryl Sulfates Using the 2,2,2-Trichloroethyl Moiety

Organic letters, 2004-01, Vol.6 (2), p.209-212

2004

Link zum Volltext

Verfügbarkeit prüfen

Le patrimoine culturel arabe dans les nouvelles de Zakariyyā Tāmir : une esthétique du grotesque

Asiatische Studien, 2022, Vol.76 (2), p.389

Dové, Peter

2022

Link zum Volltext

Verfügbarkeit prüfen

Le patrimoine culturel arabe dans les nouvelles de Zakariyyā Tāmir: Une esthétique du grotesque

Asiatische Studien, 2022-05, Vol.76 (2), p.389-406

Dové, Peter

2022

Link zum Volltext

Verfügbarkeit prüfen

Le patrimoine culturel arabe dans les nouvelles de Zakariyyā Tāmir: Une esthétique du grotesque

Asiatische Studien, 2022-04, Vol.76 (2), p.389-406

Dové, Peter

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3854: Preclinical characterization of a novel non-cyclic dinucleotide small molecule STING agonist with potent antitumor activity in mice

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3854-3854

2019

Link zum Volltext

Verfügbarkeit prüfen

TTI-281, an Orally Bioavailable Bromodomain and Extraterminal Domain (BET) Inhibitor, Is a Promising Candidate for the Treatment of Multiple Myeloma

Blood, 2016-12, Vol.128 (22), p.2095-2095

2016

Link zum Volltext

Verfügbarkeit prüfen

Genomic Characterization of the Istrian Shorthaired Hound

Animals (Basel), 2020-11, Vol.10 (11)

2020

Link zum Volltext

Verfügbarkeit prüfen

DDIS-11. TTI-2341: A NOVEL, ORALLY BIOAVAILABLE, BRAIN-PENETRANT, COVALENT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM) AND BRAIN METASTASES OF NON-SMALL CELL LUNG CANCER (NSCLC)

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi61-vi61

2017

Link zum Volltext

Verfügbarkeit prüfen

Discovery of cis-N-(1-(4-(Methylamino)cyclohexyl)indolin-6-yl)thiophene-2-carboximidamide: A 1,6-Disubstituted Indoline Derivative as a Highly Selective Inhibitor of Human Neuronal Nitric Oxide Synthase (nNOS) without Any Cardiovascular Liabilities

Journal of medicinal chemistry, 2012-01, Vol.55 (2), p.943-955

2012

Link zum Volltext

Verfügbarkeit prüfen

The Highly Potent Bromodomain (BRD) Inhibitor FV-281 Displays Preclinical Efficacy in Acute Myeloid Leukemia (AML)

Blood, 2015-12, Vol.126 (23), p.1364-1364

2015

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, and Biological Evaluation of 3,4-Dihydroquinolin-2(1H)-one and 1,2,3,4-Tetrahydroquinoline-Based Selective Human Neuronal Nitric Oxide Synthase (nNOS) Inhibitors

Journal of medicinal chemistry, 2011-08, Vol.54 (15), p.5562-5575

2011

Link zum Volltext

Verfügbarkeit prüfen

Developing citizen leadership in Myanmar: the DeBoer fellowship

International journal of public leadership, 2016-05, Vol.12 (2), p.129-142

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine

European journal of medicinal chemistry, 2012-09, Vol.55, p.94-107

2012

Link zum Volltext

Verfügbarkeit prüfen

Novel, druglike 1,7-disubstituted 2,3,4,5-tetrahydro-1H-benzo[b]azepine-based selective inhibitors of human neuronal nitric oxide synthase (nNOS)

Bioorganic & medicinal chemistry letters, 2012-04, Vol.22 (7), p.2510-2513

2012

Link zum Volltext

Verfügbarkeit prüfen

1,2,3,4-Tetrahydroquinoline-Based Selective Human Neuronal Nitric Oxide Synthase (nNOS) Inhibitors: Lead Optimization Studies Resulting in the Identification of N-(1-(2-(Methylamino)ethyl)-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide as a Preclinical Development Candidate

Journal of medicinal chemistry, 2012-03, Vol.55 (6), p.2882-2893

2012

Link zum Volltext

Verfügbarkeit prüfen

FV-082: A safer orally active broad-spectrum antiepileptic drug candidate

Epilepsy & behavior, 2015-05, Vol.46, p.57-58

2015

Link zum Volltext

Verfügbarkeit prüfen

FV-009 candidate drug: Novel and selective P/Q-type Ca2 + and voltage-gated Na+ ion channel modulation for epilepsy and pain

Epilepsy & behavior, 2015-05, Vol.46, p.57-57

2015

Link zum Volltext

Verfügbarkeit prüfen

FV-137 candidate drug: Novel and selective ion channel modulation for epilepsy and pain

Epilepsy & behavior, 2015-05, Vol.46, p.58-59

2015

Link zum Volltext

Verfügbarkeit prüfen

FV-009 candidate drug: Novel and selective P/Q-type Ca 2 + and voltage-gated Na+ ion channel modulation for epilepsy and pain

Epilepsy & behavior, 2015, Vol.46, p.57-57

2015

Link zum Volltext

Verfügbarkeit prüfen

FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo

Blood, 2013-11, Vol.122 (21), p.1988-1988

2013

Link zum Volltext

Verfügbarkeit prüfen

Isolation of Mycoplasma capricolum-like strains from chickens

Veterinary microbiology, 2006-01, Vol.112 (1), p.23-31

2006

Link zum Volltext

Verfügbarkeit prüfen

Erratum: “Born–Oppenheimer breakdown in a combined-isotopomer analysis of the A 1Σu+−X 1Σg+ system of Li2” [J. Chem. Phys. 117 , 9339 (2002)]

The Journal of chemical physics, 2004-02, Vol.120 (7), p.3520-3520

2004

Link zum Volltext

Verfügbarkeit prüfen

Functional study of the equine β-casein and κ-casein gene promoters: COST Action B20: Mammary development, function and cancer

Journal of dairy research, 2005, Vol.72, p.34-43

2005

Link zum Volltext

Verfügbarkeit prüfen

Born–Oppenheimer breakdown in a combined-isotopomer analysis of the A 1Σu+–X 1Σg+ system of Li2

The Journal of chemical physics, 2002-11, Vol.117 (20), p.9339-9346

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 222

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(186)
Mit Volltextzugriff
(207)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Slow-Dissociation and Slow-Recombination Assumptions in Nonequilibrium Capillary Electrophoresis of Equilibrium Mixtures

Synthesis and Protection of Aryl Sulfates Using the 2,2,2-Trichloroethyl Moiety

Le patrimoine culturel arabe dans les nouvelles de Zakariyyā Tāmir : une esthétique du grotesque

Le patrimoine culturel arabe dans les nouvelles de Zakariyyā Tāmir: Une esthétique du grotesque

Le patrimoine culturel arabe dans les nouvelles de Zakariyyā Tāmir: Une esthétique du grotesque

Abstract 3854: Preclinical characterization of a novel non-cyclic dinucleotide small molecule STING agonist with potent antitumor activity in mice

TTI-281, an Orally Bioavailable Bromodomain and Extraterminal Domain (BET) Inhibitor, Is a Promising Candidate for the Treatment of Multiple Myeloma

Genomic Characterization of the Istrian Shorthaired Hound

DDIS-11. TTI-2341: A NOVEL, ORALLY BIOAVAILABLE, BRAIN-PENETRANT, COVALENT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM) AND BRAIN METASTASES OF NON-SMALL CELL LUNG CANCER (NSCLC)

Discovery of cis-N-(1-(4-(Methylamino)cyclohexyl)indolin-6-yl)thiophene-2-carboximidamide: A 1,6-Disubstituted Indoline Derivative as a Highly Selective Inhibitor of Human Neuronal Nitric Oxide Synthase (nNOS) without Any Cardiovascular Liabilities

The Highly Potent Bromodomain (BRD) Inhibitor FV-281 Displays Preclinical Efficacy in Acute Myeloid Leukemia (AML)

Design, Synthesis, and Biological Evaluation of 3,4-Dihydroquinolin-2(1H)-one and 1,2,3,4-Tetrahydroquinoline-Based Selective Human Neuronal Nitric Oxide Synthase (nNOS) Inhibitors

Developing citizen leadership in Myanmar: the DeBoer fellowship

Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine

Novel, druglike 1,7-disubstituted 2,3,4,5-tetrahydro-1H-benzo[b]azepine-based selective inhibitors of human neuronal nitric oxide synthase (nNOS)

1,2,3,4-Tetrahydroquinoline-Based Selective Human Neuronal Nitric Oxide Synthase (nNOS) Inhibitors: Lead Optimization Studies Resulting in the Identification of N-(1-(2-(Methylamino)ethyl)-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide as a Preclinical Development Candidate

FV-082: A safer orally active broad-spectrum antiepileptic drug candidate

FV-009 candidate drug: Novel and selective P/Q-type Ca2 + and voltage-gated Na+ ion channel modulation for epilepsy and pain

FV-137 candidate drug: Novel and selective ion channel modulation for epilepsy and pain

FV-009 candidate drug: Novel and selective P/Q-type Ca 2 + and voltage-gated Na+ ion channel modulation for epilepsy and pain

FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo

Isolation of Mycoplasma capricolum-like strains from chickens

Erratum: “Born–Oppenheimer breakdown in a combined-isotopomer analysis of the A 1Σu+−X 1Σg+ system of Li2” [J. Chem. Phys. 117 , 9339 (2002)]

Functional study of the equine β-casein and κ-casein gene promoters: COST Action B20: Mammary development, function and cancer

Born–Oppenheimer breakdown in a combined-isotopomer analysis of the A 1Σu+–X 1Σg+ system of Li2

Suchergebnisse filtern